WHY IT MATTERS: Patients with chronic jaw and facial pain who have not found relief through standard treatments now have emerging clinical trial evidence supporting sublingual cannabis extracts as a potential therapeutic option worth discussing with their provider. CLINICAL OVERVIEW: Sublingual cannabis extract administration has demonstrated meaningful reductions in myofascial pain among patients with temporomandibular disorders, a condition historically resistant to conventional pharmacological approaches. The findings add to a growing body of evidence supporting cannabinoid-based interventions for chronic orofacial pain, where inflammation and central sensitization play significant roles.